(VIANEWS) – Harmony Biosciences Holdings (HRMY), Capital Southwest Corporation (CSWC), MFA Financial (MFA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Harmony Biosciences Holdings (HRMY)
22.2% sales growth and 29.63% return on equity
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, Harmony Biosciences Holdings has a trailing twelve months EPS of $2.13.
PE Ratio
Harmony Biosciences Holdings has a trailing twelve months price to earnings ratio of 14.3. Meaning, the purchaser of the share is investing $14.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.63%.
Volume
Today’s last reported volume for Harmony Biosciences Holdings is 395142 which is 0.3% below its average volume of 396341.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.3%, now sitting on 582.02M for the twelve trailing months.
Sales Growth
Harmony Biosciences Holdings’s sales growth for the next quarter is 22.2%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Harmony Biosciences Holdings’s EBITDA is 2.73.
2. Capital Southwest Corporation (CSWC)
21.7% sales growth and 13.74% return on equity
Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing. In lower middle market, the firm typically invests in growth financing, bolt-on acquisitions, new platform acquisitions, refinancing, dividend recapitalizations, sponsor-led buyouts, and management buyouts situations. The investment structures are Unitranche debt, subordinated debt, senior debt, first and second lien debt, and preferred and common equity. The firm makes equity co-investments alongside debt investments, up to 20% of total check and only makes non-control investments. It prefers to invest in Industrial manufacturing and services, value-added distribution, healthcare products and services, business services, specialty chemicals, food and beverage, tech-enabled services and SaaS models. The firm seeks to invest in energy services and products, industrial technologies, and specialty chemicals and products. Within energy services and products, the firm seeks to invest in each segment of the industry, including upstream, midstream and downstream, excluding exploration and production with a focus on differentiated products and services, equipment and tool rental, consumable products, and drilling and completion chemicals. Within industrial technologies, it seeks to invest in automation and process controls, handling and packaging equipment, industrial filtration and fluid handling, measurement, monitoring and testing, professional tools, and sensors and instrumentation. Within and specialty chemicals and products, the firm seeks to invest in businesses that develop and manufacture highly differentiated chemicals and products including adhesives, coatings and sealants, catalysts and absorbents, cosmeceuticals, fine chemicals, flavors and fragrances, performance lubricants, polymers, plastics and composites, chemical dispensing and filtration equipment, professional and industrial trade consumables and tools, engineered solutions for HVAC, plumbing, and electrical installations, specified high performance materials for fire protection and oilfield applications. It may also invest in exceptional opportunities in building products. The firm seeks to invest in the United States. The firm seeks to make investments ranging from $5 to $25 million in securities. It seeks to make equity investments up to $5 million and debt investments between $5 million and $20 million and co-invest in transaction size upto $40 million. It prefers to invest in companies with revenues approaching above $10 million, profitable operations, historical growth rate of at least 15 percent per year. . Within the lower middle market, it seeks to invest in with less than $15 million in EBITDA and also opportunistically invests in the upper middle market, generally defined as companies with EBITDA in excess of $50 million. In addition to making direct investments, the firm allocates capital to syndicated first and second lien term loans in the upper middle market. Criteria for Upper Middle Market Syndicated 1st Lien is EBITDA Size more than $30 million, Closing Leverage greater than 4 times, investment hold size between $5 million and $7 million, investment yield greater than 6.5%. Criteria for Upper Middle Market Syndicated 2nd Lien is EBITDA Size more than $50 million, Closing Leverage greater than 6 times, investment hold size between $5 million and $7 million, investment yield greater than 9%. It prefers to take a majority and minority stake. The firm has the flexibility to hold investments for very long period in its portfolio companies. It may also invest through warrants. The firm prefers to take Board participation in its portfolio companies. Capital Southwest Corporation was founded on April 19, 1961 and is based in Dallas, Texas.
Earnings Per Share
As for profitability, Capital Southwest Corporation has a trailing twelve months EPS of $2.34.
PE Ratio
Capital Southwest Corporation has a trailing twelve months price to earnings ratio of 10.29. Meaning, the purchaser of the share is investing $10.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.74%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 2.52 and the estimated forward annual dividend yield is 10.4%.
Yearly Top and Bottom Value
Capital Southwest Corporation’s stock is valued at $24.07 at 20:22 EST, below its 52-week high of $26.17 and way higher than its 52-week low of $17.22.
3. MFA Financial (MFA)
20.8% sales growth and 4.12% return on equity
MFA Financial, Inc., together with its subsidiaries, operates as a real estate investment trust in the United States. The company invests in residential mortgage assets, including non-agency mortgage-backed securities, agency MBS, and credit risk transfer securities; residential whole loans, including purchased performing loans, purchased credit deteriorated, and non-performing loans; and mortgage servicing rights related assets. MFA Financial, Inc. was incorporated in 1997 and is based in New York, New York.
Earnings Per Share
As for profitability, MFA Financial has a trailing twelve months EPS of $0.46.
PE Ratio
MFA Financial has a trailing twelve months price to earnings ratio of 24.54. Meaning, the purchaser of the share is investing $24.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.12%.
4. Chipotle Mexican Grill (CMG)
13.5% sales growth and 45.26% return on equity
Chipotle Mexican Grill, Inc., together with its subsidiaries, owns and operates Chipotle Mexican Grill restaurants. It sells food and beverages through offering burritos, burrito bowls, quesadillas, tacos, and salads. The company also provides delivery and related services its app and website. It has operations in the United States, Canada, France, Germany, and the United Kingdom. Chipotle Mexican Grill, Inc. was founded in 1993 and is headquartered in Newport Beach, California.
Earnings Per Share
As for profitability, Chipotle Mexican Grill has a trailing twelve months EPS of $44.45.
PE Ratio
Chipotle Mexican Grill has a trailing twelve months price to earnings ratio of 64.84. Meaning, the purchaser of the share is investing $64.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.26%.
Volume
Today’s last reported volume for Chipotle Mexican Grill is 192407 which is 13.83% below its average volume of 223295.
5. NAPCO Security Technologies (NSSC)
12.8% sales growth and 30.06% return on equity
Napco Security Technologies, Inc. develops, manufactures, and sells security products in the United States and internationally. The company offers access control systems, door-locking products, intrusion and fire alarm systems, and video surveillance systems for commercial, residential, institutional, industrial, and governmental applications. Its access control systems include various types of identification readers, control panels, PC-based computers, and electronically activated door-locking devices; and door locking devices comprise microprocessor-based electronic door locks with push button, card readers and bio-metric operation, door alarms, mechanical door locks, and simple dead bolt locks. The company's alarm systems include automatic communicators, cellular communication devices, control panels, combination control panels/digital communicators and digital keypad systems, fire alarm control panels, and area detectors; and video surveillance systems comprise video cameras, control panels, video monitors, or PCs. It also buys and resells various identification readers, video cameras, PC-based computers, and peripheral equipment for access control and video surveillance systems; offers school security products; and markets peripheral and related equipment manufactured by other companies. The company markets and sells its products primarily to independent distributors, dealers, and installers of security equipment. Napco Security Technologies, Inc. was founded in 1969 and is headquartered in Amityville, New York.
Earnings Per Share
As for profitability, NAPCO Security Technologies has a trailing twelve months EPS of $1.16.
PE Ratio
NAPCO Security Technologies has a trailing twelve months price to earnings ratio of 35.19. Meaning, the purchaser of the share is investing $35.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.06%.
Yearly Top and Bottom Value
NAPCO Security Technologies’s stock is valued at $40.82 at 20:22 EST, way under its 52-week high of $46.26 and way higher than its 52-week low of $17.76.
6. Incyte Corporation (INCY)
7.6% sales growth and 12.5% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 21.5. Meaning, the purchaser of the share is investing $21.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.3%, now sitting on 3.7B for the twelve trailing months.
Yearly Top and Bottom Value
Incyte Corporation’s stock is valued at $56.98 at 20:22 EST, way under its 52-week high of $76.04 and way above its 52-week low of $50.27.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 135.1% and 18.2%, respectively.
Sales Growth
Incyte Corporation’s sales growth is 8.5% for the ongoing quarter and 7.6% for the next.
